期刊文献+

碳酸镧治疗维持性血液透析患者高磷血症的疗效观察 被引量:4

下载PDF
导出
摘要 目的对维持性血液透析患者高磷血症采用碳酸镧治疗的效果进行分析,为临床治疗提供依据。方法 100例已经得到确诊的维持性血液透析高磷血症患者,根据入院编号分组,单号为对照组,双号为实验组,各50例。对照组患者给予碳酸钙治疗,实验组患者给予碳酸镧治疗,比较两组患者治疗前、治疗3个月后碱性磷酸酶(AKP)、甲状旁腺激素(PTH)、血磷和血钙水平。观察两组并发症情况。结果治疗前,两组患者AKP、PTH、血磷和血钙水平比较差异均无统计学意义(P>0.05);与治疗前比较,治疗3个月后对照组血钙水平升高、血磷水平下降,实验组血钙、血磷水平均下降,且实验组血钙、血磷水平均低于对照组,差异具有统计学意义(P<0.05);治疗3个月后两组PTH、AKP水平均无明显变化,差异无统计学意义(P>0.05)。实验组患者并发症发生率为10.0%,低于对照组的34.0%,差异具有统计学意义(P<0.05)。结论碳酸镧治疗维持性血液透析高磷血症患者,其降低血磷的临床作用更为明显,比常规的碳酸钙治疗效果更为确切,且不会增加高钙血症的危险,值得临床推广。
出处 《中国实用医药》 2017年第21期132-133,共2页 China Practical Medicine
  • 相关文献

参考文献10

二级参考文献116

  • 1Dony D C. Renal bone diseases Proceedings of 4th Asian Pacific Congress of Nephrology. Dzakarta: International Academic Publishers, 1991 : 86.
  • 2Simmons R G, Abress L. Quality-cf-life issues for endstage renal diseases patients. Am J Kidney Dis, 1990, 15(3) : 201.
  • 3Yasmin Maor, Miri King, Liraz Olmer, et al. A comparison of three measures: the time trade-off technique, global health-related quality of life and the SF-36 in dialysis patients. J Clinical Epidemiology, 2001, 54:565-570.
  • 4Kates DM, Andress DL: Control of hyperphosphatemia in renal failure: role of aluminum. Semin Dial, 9:301-315, 1996.
  • 5Sperschneider H, Gunther K, Marzoll I, et al. Calcium carbonate(CaCO3): an efficient and safe phosphate binder in haemodialysis patients? A 3-year study, Nephrol Dial Transplant, 1993; 8:530-534.
  • 6Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. NEnglJMed, 2000; 342(485): 1478-1483.
  • 7Schaefer K. Alternative phosphate binders: an update. Nephrol Dial Transplant, 1993; 1(2): 35-39.
  • 8Locatelli F, D'Amico M. Lanthanum carbonate AnorMED. Curr Opin Cardiovasc Pulmon Renal Invest Drugs, 2000; 2 (4): 372-377.
  • 9D'Haese PC. Spasovski GB. Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International-Supplement, 2003; 1(85): S73-78.
  • 10Joy MS, Finn WF. LAM-302 Study Group; Randomized, doubleblind, placebo-controlled, dose-titration, phase Ⅲ study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. American Journal of Kidney Diseases, 2003; 42(1): 96-107.

共引文献94

同被引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部